Annexon Files Automatic Shelf Registration for Up to $150M At-The-Market Equity Offering

summarizeSummary

Annexon, Inc. filed an automatic shelf registration statement, including a prospectus for an At-The-Market (ATM) equity offering of up to $150 million of common stock, formalizing a capital raise program previously disclosed.

check_boxKey Events

• Formalizes $150M At-The-Market (ATM) Offering

  Annexon filed an S-3ASR to register various securities, including a sales agreement prospectus for an ATM equity offering of up to $150 million of common stock. This formalizes the program previously disclosed in the company's 10-K on March 30, 2026.

• Potential for Significant Share Dilution

  The ATM program could result in the issuance of approximately 30 million new shares, representing a potential dilution of over 20% to current shareholders, based on an assumed offering price of $5.00 per share.

• Proceeds for General Corporate Purposes

  Net proceeds from the offering are earmarked for working capital, general corporate purposes, research and development expenses, and potential in-licensing or acquisitions.

auto_awesomeAnalysis

This S-3ASR filing formalizes Annexon's ability to raise up to $150 million through an At-The-Market (ATM) equity offering, which was initially disclosed in its 10-K report filed on the same day. The program allows Annexon to sell common stock from time to time through TD Securities (USA) LLC, acting as agent, with commissions up to 3.0%. If the entire $150 million is raised at the assumed price of $5.00 per share, it would result in the issuance of approximately 30 million new shares, representing a potential dilution of over 20% to existing shareholders. The proceeds are intended for general corporate purposes, including research and development, and to extend the company's cash runway. This capital raise is substantial relative to the company's market capitalization and provides necessary funding for ongoing operations and clinical programs.